3 unchanged sentences
We have not historically paid cash dividends and do not currently anticipate paying cash dividends in the future.
−Removed: Issuer Purchases of Equity Securities
−Removed: In August 2022, the Company announced that its Board of Directors had approved a three-year share repurchase program authorizing the repurchase of up to $300.0 million of Haemonetics common stock (the “Share Repurchase Authorization”), based on market conditions, through August 2025.
−Removed: Under the share repurchase program, the Company is authorized to repurchase, from time to time, outstanding shares of common stock in accordance with applicable laws on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions.
−Removed: In February 2025, the Company entered into an accelerated share repurchase agreement (“ASR”) with Goldman Sachs & Co.
−Removed: (“Goldman Sachs”) to repurchase $150.0 million o f the Company’s common stock.
−Removed: Pursuant to the terms of the ASR, in February 2025, the Company paid Goldman Sachs $150.0 million in cash and received an initial delivery of 2.0 million shares of the Company’s common stock based on the closing market price on the New York Stock Exchange on February 7, 2025 of $59.34.
−Removed: This initial delivery of shares represented approximately 80% of the notional amount of the ASR.
−Removed: The ASR was completed in April 2025, subsequent to the end of the fourth quarter of fiscal 2025, and 0.4 million additional shares were delivered upon settlement.
−Removed: As of March 29, 2025, we have fully funded the $300.0 million Share Repurchase Authorization.
The following table provides information on the Company’s share repurchases during the fourth quarter of fiscal 2026:
−Removed: Total Number of Shares Purchased Average Price Paid per Share Total Number of Shares Purchased as Part of Publicly Announced Program Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program (in millions)
+Added: Total Number of Shares Purchased Average Price Paid per Share Total Number of Shares Purchased as Part of Publicly Announced Program (1)(2)
+Added: Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program
+Added: (Dollars in Thousands, Except Per Share Data)
December 28, 2025 – January 24, 2026 131,937 $ 69.97 131,937 $ 415,768
2 unchanged sentences
Total 1,579,255 1,579,255
−Removed: Share Repurchase Authorization
−Removed: In April 2025 the Company’s Board of Directors approved a new share repurchase authorization of up to $500 million of the Company’s common stock over the next three years.
−Removed: This new share repurchase program will help to offset the dilutive impact of recent and future employee equity grants.
−Removed: In addition to this share repurchase activity, the Company’s capital allocation strategy continues to prioritize funding of planned internal investments to support the business as well as inorganic opportunities to accelerate its long-term growth plans.
−Removed: Under the share repurchase program, the Company is authorized to repurchase, from time to time, outstanding shares of common stock in accordance with applicable laws on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions.
−Removed: The actual timing, number and value of shares repurchased will be determined by the Company at its discretion and will depend on a number of factors, including market conditions, applicable legal requirements and compliance with the terms of loan covenants.
−Removed: The share repurchase program may be suspended, modified or discontinued at any time, and the Company has no obligation to repurchase any amount of its common stock under the program.
+Added: (1) In April 2025, our Board approved a three-year share repurchase program authorizing the repurchase of up to $500.0 million of Haemonetics common stock, based on market conditions, through April 2028.
+Added: Under the 2025 share repurchase program, shares may be repurchased in accordance with applicable laws both on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions.
+Added: (2) During the fourth quarter of fiscal 2026, we repurchased $25.0 million of our common stock pursuant to a previously executed Rule 10b5-1 trading plan.
+Added: The total number of shares repurchased pursuant to the Rule 10b5-1 trading plan was 360,457 at an average price per share upon final settlement of $69.36.
+Added: In March 2026, we completed a $75.0 million repurchase of our common stock pursuant to an accelerated share repurchase agreement (“ASR”) entered into with Goldman Sachs & Co.
+Added: (“Goldman Sachs”) in February 2026.
+Added: The total number of shares repurchased under the ASR was 1,218,798 at an average price per share upon final settlement of $61.54.
+Added: As of March 28, 2026, the total remaining authorization for repurchases of our common stock under the share repurchase program was $325.0 million.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.